Medicis ships Restylane, Perlane after FDA nod

Scottsdale, Ariz.

- Medicis, based here, has begun shipping dermal fillers Restylane-L and Perlane-L (both hyaluronic acid/lidocaine), GlobeNewswire reports.

The Food and Drug Administration (FDA) on Jan. 29 approved Restylane-L for implantation into the mid- to deep dermis and Perlane-L for implantation into the deep dermis to superficial subcutis. Both fillers are intended for the correction of moderate to severe facial wrinkles, such as nasolabial folds.

GlobeNewswire quotes Medicis Chairman and CEO Jonah Shacknai as saying, “We are pleased to be shipping Restylane-L and Perlane-L just two weeks after announcing FDA approval. Restylane is the first and only hyaluronic acid dermal filler approved to last up to 18 months with one repeat treatment. We believe the addition of 0.3 percent lidocaine to Restylane ... and Perlane is an offering physicians and their patients will appreciate.”